The Dynamics And Value Of Cross-Border Biotech

By Jonathan Gertler

The Nordic region has the right ingredients for advancing biotechnology: strong academic and technology communities, seasoned management in both international pharma and local entrepreneurial efforts, and a growing capital base. As biotechnology globalizes, the strategies and tactics these countries and companies need are no different than the approaches made by developing and established companies in Boston and San Francisco.

Last fall, global biotech leaders came together at a life sciences symposium in Copenhagen to share their insights on cross-border development and to discuss the creation of sustainable and independent companies based in a vibrant — but smaller — biotechnology cluster.